Cronos Group Inc (CRON) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cronos Group Inc stock (CRON) is currently trading at $2.58. Cronos Group Inc PS ratio (Price-to-Sales) is 6.66. Analyst consensus price target for CRON is $2.29. WallStSmart rates CRON as Sell.
- CRON PE ratio analysis and historical PE chart
- CRON PS ratio (Price-to-Sales) history and trend
- CRON intrinsic value — DCF, Graham Number, EPV models
- CRON stock price prediction 2025 2026 2027 2028 2029 2030
- CRON fair value vs current price
- CRON insider transactions and insider buying
- Is CRON undervalued or overvalued?
- Cronos Group Inc financial analysis — revenue, earnings, cash flow
- CRON Piotroski F-Score and Altman Z-Score
- CRON analyst price target and Smart Rating
Cronos Group Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Cronos Group Inc (CRON) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, eps growth. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Cronos Group Inc (CRON) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 47.00% year-over-year
Earnings per share surging 238.80% year-over-year
Supporting Valuation Data
Cronos Group Inc (CRON) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Premium valuation at 6.7x annual revenue
Low institutional interest, mostly retail-driven
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Cronos Group Inc (CRON) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth, EPS Growth. Valuation metrics including Price/Book (0.90) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 47.00%, EPS Growth at 238.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (6.66) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -0.26%, Operating Margin at -10.10%, Profit Margin at -6.45%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -0.26% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 47.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CRON Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CRON's Price-to-Sales ratio of 6.66x trades at a deep discount to its historical average of 386.98x (6th percentile). The current valuation is 100% below its historical high of 7177.54x set in Dec 2017, and 14% above its historical low of 5.83x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~5.8x, reflecting growing market expectations outpacing revenue growth.
Compare CRON with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Cronos Group Inc (CRON) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Cronos Group Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 147M with 47% growth year-over-year. The company is currently unprofitable, posting a -6.5% profit margin.
Key Findings
Revenue growing at 47% YoY, reaching 147M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 10M in free cash flow and 12M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -6.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Cronos Group Inc maintain 47%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Cronos Group Inc.
Bottom Line
Cronos Group Inc is a high-conviction growth story with revenue accelerating at 47% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -6.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cronos Group Inc(CRON)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Cronos Group Inc. is a cannabinoid company. The company is headquartered in Toronto, Canada.